Rockwell Medical, Inc. RMTI
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -14.82%
- 1 year
- -34.54%
- Open
- 6.94
- Prev close
- 7.31
- Mkt cap
- 28.50M
- Vol
- 39.54K
- Avg vol
- 25.91K
- EPS
- -1.34
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.71
- High
- 7.08
- Forward P/E
- 30.14
- Beta
- 1.50
- Short ratio
- 1.51
- Inst. own
- 21.27%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.92
- 200-d avg
- 2.38
- 1y target
- 6.50
Key statistics
- Market cap
- 68.19M
- Enterprise value
- 90.33M
- Trailing P/E
- 0.00
- Forward P/E
- 30.14
- PEG ratio
- 0.00
- Price / sales
- 0.72
- Price / book
- 2.89
- EPS (TTM)
- -0.04
- Beta
- 1.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -5.06%
- Revenue (TTM)
- 94.37M
- Revenue growth
- 42.90%
- Free cash flow
- -2.37M
- Total cash
- 11.86M
- Total debt
- 14.38M
- Return on equity
- -28.90%
- Shares outstanding
- 32.32M
- Short % of float
- 2.67%
- 50-day average
- 2.92
- 200-day average
- 2.38
Analyst view
Consensus: none
- Target (low)
- 6.00
- Target (mean)
- 6.50
- Target (high)
- 7.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.01 | 0.05 | +0.04 | +400.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.04 | 0.01 | +0.05 | +125.00% |
| May 14, 2024 | Mar 1, 2024 | -0.05 | -0.02 | +0.03 | +60.00% |
| Mar 21, 2024 | Dec 1, 2023 | -0.08 | 0.02 | +0.10 | +125.00% |
| Nov 14, 2023 | Sep 1, 2023 | -0.12 | -0.07 | +0.05 | +41.67% |
| Aug 14, 2023 | Jun 1, 2023 | -0.12 | -0.18 | -0.06 | -50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 14, 2024 | Rodman & Renshaw | init | — | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 25, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Rockwell Medical, Inc.
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- rockwellmed.com
News
- Rockwell Medical to Release Third Quarter 2026 Results on Thursday, November 12, 2026
- Rockwell Medical to Exhibit at ASN Kidney Week 2026
- Rockwell Medical Ranked No. 16 on the 2026 Fortune ‘Best Workplaces in Manufacturing & Production' List
- Reviewing Rockwell Medical (NASDAQ:RMTI) & Embecta (NASDAQ:EMBC)
- HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $20 Price Target
- Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
- Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates
- Rockwell Medical Announces Second Quarter 2026 Results
- Rockwell Medical Q2 Adj. EPS $(0.04) Beats $(0.23) Estimate, Sales $17.780M Miss $17.837M Estimate
- Rockwell Medical Affirms FY2026 Sales Guidance of $70.000M-$75.000M vs $72.469M Est
Your note
Sign in to keep a note on RMTI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHOLE TIMOTHY | Officer | Sale | Sep 30, 2024 | 55,171 |
| COOPER JOHN G | Director | Stock Award(Grant) | May 20, 2024 | 95,451 |
| LAU JOAN | Director | Stock Award(Grant) | May 20, 2024 | 63,111 |
| NERI JESSE | Officer | Stock Award(Grant) | Mar 13, 2024 | 33,330 |
| NISSENSON ALLEN R | Director | Stock Award(Grant) | May 20, 2024 | 92,597 |
| RADIE ROBERT SAMUEL | Director | Stock Award(Grant) | May 20, 2024 | 93,525 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 11.08% | 3,581,525 | 7.56M | Sep 29, 2024 |
| Vanguard Group Inc | 3.73% | 1,203,910 | 2.54M | Sep 29, 2024 |
| Globeflex Capital L P | 2.30% | 743,256 | 1.57M | Sep 29, 2024 |
| Marshall Wace LLP | 1.57% | 508,674 | 1.07M | Sep 29, 2024 |
| Perkins Capital Management, Inc. | 1.08% | 350,376 | 739.29K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.95% | 307,294 | 648.39K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.51% | 811,895 | 1.71M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.10% | 355,638 | 750.40K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.49% | 157,335 | 331.98K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.21% | 69,300 | 146.22K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 52,977 | 111.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 37,836 | 79.83K | Oct 30, 2024 |